Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218358 | 0.79 | DRD2 (0.36) | MAPTPOLBKDM4ECYP1A2CYP2C9 | |
| SCHEMBL8321938 | 0.77 | HPGD (0.47) | HPGDMAPTKMT2APOLBKDM4E | |
| SCHEMBL23218548 | 0.77 | HPGD (0.40) | HPGDMAPTKMT2APOLBKDM4E | |
| SCHEMBL2402264 | 0.76 | MAPT (0.39) | HPGDMAPTKMT2APOLBKDM4E | |
| SCHEMBL17274555 | 0.74 | HPGD (0.44) | HPGDMAPTKMT2APOLBKDM4E | |
| SCHEMBL23606883 | 0.70 | MEN1 (0.40) | KMT2APOLBCYP1A2CYP2C9ALOX15 | |
| SCHEMBL1509536 | 0.68 | ALOX15 (0.45) | HPGDMAPTKMT2APOLBKDM4E | |
| SCHEMBL20869030 | 0.68 | AAK1 (0.47) | HPGDKMT2ASMN1; SMN2MEN1RAB9A | |
| SCHEMBL17295202 | 0.67 | KMT2A (0.56) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL17290344 | 0.67 | KMT2A (0.56) | MAPTKMT2ASMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | HPGD 695/4885MAPT 4793/4885KMT2A 4445/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | HPGD 323/4885MAPT 3561/4885KMT2A 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.